Intravitreal faricimab in patients with nAMD: French data from the Fight Retinal Blindness! Registry
In brief
Faricimab extends injection intervals from 6 to 8.4 weeks in treated eyes
In a French registry study of previously treated neovascular age-related macular degeneration, the average injection interval grew from 6 to 8.4 weeks at 12 months, while vision remained stable. The gain was larger in eyes with inactive disease, and half of active eyes became inactive; because this was observational, it remains unclear whether faricimab or other factors drove the changes.
- Journal
- Acta ophthalmologica (Q1)
- Published
- 6 October 2026
- Study design
- Prospective / inception cohort
- Evidence level
- Level 2, Moderate (CEBM 2b)
- Authors
- Eloi Debourdeau, Déborah Harboun, Pierre-Henry Gabrielle, Yohei Hashimoto, Chloe Chamard, Frederic Michon, et al.
- PMID
- 42837224
- DOI
- 10.1111/aos.70251
Why clinicians should know about it
- Picked for Ophthalmology (paper of the day, 7 October 2026): Real‑world faricimab outcomes in neovascular AMD
Abstract
PURPOSE: To assess real-world outcomes of intravitreal faricimab in French patients with neovascular age-related macular degeneration (nAMD) previously treated with vascular endothelial growth factor (VEGF) inhibitors using data from the Fight Retinal Blindness! (FRB!) Registry. METHODS: Retrospective analysis of prospectively collected FRB! Registry data (November 2023-March 2026) on eyes switched to faricimab from other VEGF inhibitors. PRIMARY ENDPOINT: change in injection interval at 12 months. Secondary endpoints: macular neovascularization (MNV) inactivation, visual acuity (VA), injections, switch-off, safety. Mixed-effects models assessed baseline predictors of interval change and loading-dose effect on MNV inactivation. RESULTS: We included 222 eyes (169 patients; mean [SD] age 81.4 [7.8] years; VA 64.6 [19.3] letters; interval 5.9 [3.5] weeks; 26.2 prior injections); 143 (64.4%) were 12-month completers. Mean interval increased from 6.0 to 8.4 weeks (p < 0.001), with a greater gain in inactive (Δ +4.0 weeks) than active eyes (Δ +1.7 weeks; p = 0.033). VA remained stable (Δ -0.8 letters; p = 0.28). Inactive MNV rose from 36% to 60% (p < 0.001); 50% of active eyes achieved inactivation. After adjustment, MNV activity at switch was the only predictor of interval reduction (vs. inactive: SRFl only, β = -2.8 weeks, p = 0.015; IRF/haemorrhage, β = -2.4 weeks, p = 0.020). A loading dose was not associated with interval extension (p = 0.59) or MNV inactivation (p = 0.50). Intraocular inflammation occurred in 5 eyes (2.3%). CONCLUSION: Macular neovascularization (MNV) inactivation and modest interval extension were observed in active eyes; inactive eyes showed a larger interval extension. Loading dose was not associated with better outcomes in this observational cohort. Safety was acceptable.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.